Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

NCT07285239 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Arm A: Belantamab Mafodotin
DRUG: Arm B: Daratumumab Hyaluronidase
DRUG: Bortezomib
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

PrECOG, LLC.

Collaborators

[object Object]